Kenvue, the company behind Tylenol and a long list of over the counter health and personal care brands, is cutting hundreds of jobs as it gets ready to be absorbed by Kimberly-Clark. Company leaders are framing the move as a way to streamline operations before the handoff, with corporate and support roles in the crosshairs and a reduction that works out to a single digit percentage of Kenvue's global workforce.
According to Reuters, the board signed off on an "operating model optimization" that will trim about 3.5% of Kenvue's roughly 22,000 employees, or about 770 roles, and is expected to trigger around $250 million in pre tax restructuring charges in 2026. Reuters noted that the layoff news landed alongside Kenvue's fourth quarter earnings, which the company said came in ahead of Wall Street forecasts.
Quarterly Results and the Cost Picture
On the numbers side, Kenvue reported that its self care segment, which includes brands like Tylenol and Benadryl, generated $1.59 billion in net sales for the fourth quarter, while overall Q4 net sales reached about $3.78 billion, according to the investor release posted via Nasdaq/Business Wire. Company leadership said the restructuring is aimed at shoring up profit margins as Kenvue moves toward closing the Kimberly-Clark deal.
Kimberly-Clark Deal Context
The job cuts arrive as Kimberly-Clark pursues a roughly $48.7 billion cash and stock acquisition of Kenvue that would roll household names like Tylenol, Band-Aid and Listerine into a larger consumer health portfolio. The takeover values Kenvue at about $21.01 per share and is expected to close in the second half of 2026, according to Fortune.
Local Angle: Irving and DFW
Because Kimberly-Clark is headquartered in Irving, Texas, the deal and the planned job cuts are already on the radar of the Dallas-Fort Worth corporate crowd, where acquirers frequently consolidate overlapping back office and support functions. As reported by the Dallas Business Journal, Kenvue has described the layoffs as part of an effort to capture operational efficiencies ahead of the merger.
What Workers Can Expect
In its investor statement, Kenvue said it will book one time restructuring charges this year and, given the pending transaction, will skip the usual quarterly earnings conference call, according to the release posted via Nasdaq/Business Wire. The company has not laid out a site by site schedule for when jobs will be cut. In restructurings like this, next steps typically include employee consultations, federally required WARN Act notices where they apply, and severance or transition support packages for those whose roles are eliminated.
Legal and Financial Backdrop
All of this is playing out as Kenvue deals with legal and reputational trouble that has drawn national attention, including a high profile state lawsuit and related regulatory scrutiny over how it has marketed prenatal acetaminophen. Reuters has highlighted those pressures as part of the backdrop for Kenvue's recent push to cut costs ahead of the Kimberly-Clark takeover.
.jpg){kind=link}